Visnadine is a natural product extracted from the seeds and aerial parts of Ammi visnaga (Umbelliferae), plant widely used in Egyptian medicine since the Pharaohs times as antispastic and for the treatment of angina pectoris and other cardiovascular diseases. It has been used since a long time in western medicine for the treatment of various cardiac diseases and peripheral vasculopathies. Visnadine seems to act by inhibiting the contractile responses mediated by Ca2+ entry through L-type Ca2+ channels.Topical use of Visnadine may increase regional vascularization afecting turgidity and sensorial threshold of the area of application. A formulation for vulvar application (ReFeel® spray, IDI Integratori Dietetici Italiani S.r.l., Italy) has been developed and it contains Visnadine at high concentration (1%) with an elevate purity index (minimum 95%). Visnadine spray displayed positive effects on sexual function in women with and without FSD and it was well tolerated. Topical Visnadine may not only be part of multimodal strategies to manage clinically relevant sexual symptoms but also simply to help women to enhance their subjective impaired perception of sexual response.

Aclatonium (also known as aclatonium napadisilate) is a cholinergic agonist that has been developed and used in Asia as an activator of gastrointestinal motility.

Acetiromate was studied to treat patients with hyperlipidemia.

Didrovaltrate is an active compound derived from Valeriana plant. In experiments with rat HTC cells, didrovaltrate showed considerable cytotoxicity which made it a promising agent for the treatment of cancer. There are no clinical trials available on the drug, however, there are studies reporting its clinical use (under the name Valmane) in patients with kidney cancer, oral cavity cancer, breast cancer and lung cancer. It is believed that the drugs acts by inhibiting the protein synthesis. The current marketing status of the drug is unknown and supposed to be "discontinued".

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

Chloroprednisone acetate is the 21-acetate ester of chloroprednisone. Chloroprednisone acetate was sold under the brand name Topilan as an anti-inflammatory agent.

Cyproterone belongs to a group of medications known as steroidal antiandrogens. It suppresses testosterone and its metabolites. It has approximately three-fold lower potency as an antagonist of the androgen receptor relative to cyproterone acetate. Cyproterone acetate is used to treat advanced prostate cancer and acne.

Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.

Esonarimod (KE-298), a derivative of propionic acid developed in Japan, has been shown to suppress various animal models of arthritis by inhibiting the production of inflammatory cytokines, such as IL-1β, IL-6 and IL-8, from human peripheral blood mononuclear cells. In vitro, the two stereoisomers showed equivalent potency for antagonism of interleukin-1 and enhancement of lymphocyte transformation. Esonarimod also inhibited tumour necrosis factor-α-induced proliferation of synovial cells. Inhibition of proliferation of cells was not due to nonspecific cytotoxicity. Treatment with esonarimod also significantly reduced chloramphenicol acetyltransferase activity in synovial cells, and diminished activity of the transcription factor AP-1 in the nucleus of synovial fibroblast-like cells. In a phase II trial among 60 patients with rheumatoid arthritis, esonarimod 100-200 mg/day PO for 12 weeks produced significant improvements in the Lansbury index.

Racecadotril (acetorphan) is an oral enkephalinase inhibitor for use in the treatment of acute diarrhea. Racecadotril reduces hypersecretion of water and electrolytes into the intestinal lumen, by preventing the degradation of endogenous enkephalins. Treatment with racecadotril reduces the incidence and duration of acute diarrhea and reduces diarrhea-associated symptoms compared with placebo in adults. Racecadotril treatment also results in significant reductions in stool output compared with placebo in infants and young children aged 2 months to 4 years with acute diarrhea. Both rotavirus-negative and rotavirus-positive infections appear to respond to treatment in the pediatric populations investigated for this infection. Racecadotril shows similar or slightly reduced efficacy to loperamide in the treatment of diarrhea in adults and children aged up to 10 years. However, in comparative trials, racecadotril was associated with fewer adverse events than loperamide, in particular, post-treatment constipation. Racecadotril is available in France (where it was first introduced in ~1990) and other European countries (including Germany, Italy, the UK, Spain and the Czech Republic) as well as most of South America and some South East Asian countries (including China, India and Thailand), but not in the United States.